Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial - PubMed (original) (raw)

Randomized Controlled Trial

. 2011 Jul 23;378(9788):319-27.

doi: 10.1016/S0140-6736(11)60895-7. Epub 2011 Jun 27.

Brian Bundy, Dorothy J Becker, Linda A DiMeglio, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Carla J Greenbaum, Kevan C Herold, Jennifer B Marks, Roshanak Monzavi, Antoinette Moran, Tihamer Orban, Jerry P Palmer, Philip Raskin, Henry Rodriguez, Desmond Schatz, Darrell M Wilson, Jeffrey P Krischer, Jay S Skyler; Type 1 Diabetes TrialNet GAD Study Group

Collaborators, Affiliations

Randomized Controlled Trial

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial

Diane K Wherrett et al. Lancet. 2011.

Abstract

Background: Glutamic acid decarboxylase (GAD) is a major target of the autoimmune response that occurs in type 1 diabetes mellitus. In animal models of autoimmunity, treatment with a target antigen can modulate aggressive autoimmunity. We aimed to assess whether immunisation with GAD formulated with aluminum hydroxide (GAD-alum) would preserve insulin production in recent-onset type 1 diabetes.

Methods: Patients aged 3-45 years who had been diagnosed with type 1 diabetes for less than 100 days were enrolled from 15 sites in the USA and Canada, and randomly assigned to receive one of three treatments: three injections of 20 μg GAD-alum, two injections of 20 μg GAD-alum and one of alum, or 3 injections of alum. Injections were given subcutaneously at baseline, 4 weeks later, and 8 weeks after the second injection. The randomisation sequence was computer generated at the TrialNet coordinating centre. Patients and study personnel were masked to treatment assignment. The primary outcome was the baseline-adjusted geometric mean area under the curve (AUC) of serum C-peptide during the first 2 h of a 4-h mixed meal tolerance test at 1 year. Secondary outcomes included changes in glycated haemoglobin A(1c) (HbA(1c)) and insulin dose, and safety. Analysis included all randomised patients with known measurements. This trial is registered with ClinicalTrials.gov, number NCT00529399.

Findings: 145 patients were enrolled and treated with GAD-alum (n=48), GAD-alum plus alum (n=49), or alum (n=48). At 1 year, the 2-h AUC of C-peptide, adjusted for age, sex, and baseline C-peptide value, was 0·412 nmol/L (95% CI 0·349-0·478) in the GAD-alum group, 0·382 nmol/L (0·322-0·446) in the GAD-alum plus alum group, and 0·413 nmol/L (0·351-0·477) in the alum group. The ratio of the population mean of the adjusted geometric mean 2-h AUC of C-peptide was 0·998 (95% CI 0·779-1·22; p=0·98) for GAD-alum versus alum, and 0·926 (0·720-1·13; p=0·50) for GAD-alum plus alum versus alum. HbA(1c), insulin use, and the occurrence and severity of adverse events did not differ between groups.

Interpretation: Antigen-based immunotherapy therapy with two or three doses of subcutaneous GAD-alum across 4-12 weeks does not alter the course of loss of insulin secretion during 1 year in patients with recently diagnosed type 1 diabetes. Although antigen-based therapy is a highly desirable treatment and is effective in animal models, translation to human autoimmune disease remains a challenge.

Funding: US National Institutes of Health.

Copyright © 2011 Elsevier Ltd. All rights reserved.

PubMed Disclaimer

Figures

Figure 1

Figure 1

(A): Enrollment, Randomization, and Follow-up of Study Participants. (B): Rate of enrollment over time. Indicated is the point at which approval was granted to change the lower age for eligibility of enrollment from 16 years to 3 years.

Figure 1

Figure 1

(A): Enrollment, Randomization, and Follow-up of Study Participants. (B): Rate of enrollment over time. Indicated is the point at which approval was granted to change the lower age for eligibility of enrollment from 16 years to 3 years.

Figure 2

Figure 2

(A): The population mean (and 95% confidence intervals) of stimulated C-peptide 2-hour AUC mean (expressed as nmol/L) over time for each treatment group. The estimates are from the analysis of covariance model adjusting for age, gender, baseline value of C-peptide, and treatment assignment. Y-axis is on a log(y + 1) scale. (B): The fitted line representing the population mean of stimulated C-peptide 2-hour AUC mean over time for each treatment group. The estimates are from the analysis of mixed effects model adjusting for age, gender, baseline value of C-peptide, and treatment assignment, and including a fixed effect for time as a linear line on the log(y + 1) scale. (C): The proportion of subjects with 2 hour peak C-peptide remaining at or above 0.2 nmol/L over time for each treatment group.

Figure 2

Figure 2

(A): The population mean (and 95% confidence intervals) of stimulated C-peptide 2-hour AUC mean (expressed as nmol/L) over time for each treatment group. The estimates are from the analysis of covariance model adjusting for age, gender, baseline value of C-peptide, and treatment assignment. Y-axis is on a log(y + 1) scale. (B): The fitted line representing the population mean of stimulated C-peptide 2-hour AUC mean over time for each treatment group. The estimates are from the analysis of mixed effects model adjusting for age, gender, baseline value of C-peptide, and treatment assignment, and including a fixed effect for time as a linear line on the log(y + 1) scale. (C): The proportion of subjects with 2 hour peak C-peptide remaining at or above 0.2 nmol/L over time for each treatment group.

Figure 3

Figure 3

(A): The population mean of HbA1c over time for each treatment group. The estimates are from the analysis of covariance model adjusting for age, gender, baseline value of HbA1c, and treatment assignment. (B): The population mean of insulin use per kilogram of body weight over time (in 3 month interval) for each treatment group. The estimates are from the analysis of covariance model adjusting for age, gender, baseline value of HbA1c, and treatment assignment.

Figure 4

Figure 4

(A): The ratio (GAD-alum ×3 to alum ×3) of treatment effect on 1 year stimulated C-peptide AUC mean within categories of pre-specified baseline factors. The estimates are from the analysis of covariance modeling log of C-peptide adjusting for age, gender, baseline value of C-peptide, the indicated categorized factor, treatment assignment, and treatment interaction terms. The homogeneity test of treatment effect was significant for DR3 allele status (p = 0.04). (B): The ratio (GAD-alum ×2 to alum ×3) of treatment effect on 1 year stimulated C-peptide AUC mean within categories of pre-specified baseline factors. The estimates are from the analysis of covariance modeling log of C-peptide adjusting for age, gender, baseline value of C-peptide, the indicated categorized factor, treatment assignment, and treatment interaction terms.

Comment in

Similar articles

Cited by

References

    1. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001;358:221–229. - PubMed
    1. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001 Diabetes. 2004;53:250–264. - PubMed
    1. Diabetes Control and Complications Trial Research Group: Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial: a randomized, controlled trial. Ann Intern Med. 1998;128:517–523. - PubMed
    1. Steffes MW, Sibley S, Jackson M, Thomas W, Steffes MW, Sibley S, et al. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care. 2003;26:832–836. - PubMed
    1. Feutren G, Assan R, Karsenty G, Du Rostu H, Sirmai J, Papoz L, et al. Cyclosporin increases the rate and length of remission in insulin-dependent diabetes of recent onset: results of a multicentre double-blind trial. Lancet. 1986;328:119–124. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources